# A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

> **NCT02072824** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 175 (actual)

## Conditions studied

- Partial Onset Seizures

## Interventions

- **DRUG:** Pregabalin Dose Level 1
- **DRUG:** Pregabalin Dose Level 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02072824
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-16
- **Primary completion:** 2018-03-13
- **Final completion:** 2018-03-13
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072824, "A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02072824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*